Skip to main content

Table 2 Signs and symptoms evaluated during the clinical trial

From: Clinical efficacy and tolerability of an immune-stimulant* constituted by inactivated bacterial bodies in the prophylaxis of infectious episodes of airways: a double blind, placebo-controlled, randomized, multicentre study

   Months 0-4 Months 4-6
   Placebo N (%) Buccalin N (%) Placebo N (%) Buccalin N (%)
Cough intensity Weak 29 (49.2) 42 (57.5) 4 (50.0) 2 (40.0)
  Moderate 26 (44.1) 30 (41.1) 2 (25.0) 2 (40.0)
  Severe 4 (6.8) 1 (1.4) 2 (25.0) 1 (20.0)
  Total 59 73 8 5
Dyspnoea Weak 9 (52.9) 19 (70.4) 1 (33.3) 1 (33.3)
  Moderate 6 (35.3) 8 (29.6) 0 (0.0) 1 (33.3)
  Severe 2 (11.8) 0 (0.0) 2 (66.7) 1 (33.3)
  Total 17 27 3 3
Pain Weak 16 (69.6) 26 (63.4) 4 (80.0) 4 (80.0)
  Moderate 7 (30.4) 15 (36.6) 0 (0.0) 1 (20.0)
  Severe 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0)
  Total 23 41 5 5
Fever Weak 8 (30.8) 11 (32.4) 1 (25.0) 1 (50.0)
  Moderate 17 (65.4) 23 (67.6) 2 (50.0) 1 (50.0)
  Severe 1 (3.8) 0 (0.0) 1 (25.0) 0 (0.0)
  Total 26 34 4 2